论文部分内容阅读
Ex vivo engineering of antigens and vaccine adjuvant to enhance DCs antigen swallow and present efficiency and also to improve the degree of its maturation which directly related to its homing capacity and T cells activation.In the current work,we choose the well-known peptides SIINFEKL and CpG,a TLR-9 agonist,which has been shown both in preclinical and clinical studies to promote Th1-responses,as the antigen and vaccine adjuvant respectively.